- Price
- $12.29
- Day
- +3.45%
- Mkt Cap
- $1.14B
- 52W Range
- $6.62 – $15.35
- Volume
- 554.2K
- Beta
- 1.21
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
MeiraGTx Holdings plc is positioned potentially for significant upside with late-stage gene therapy assets targeting large, high-unmet-need indications. AAV2-hAQP1 for radiation-induced xerostomia could address a $3.7B peak sales market with no direct competition; pivotal Phase 2 data expected 2Q27. Robust optionality from GAD for Parkinson's, bota-vec for XLRP, milestone payments, and the innovative Riboswitch platform enhances MGTX's valuation case.
Read full article
The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read full article